Resource Library

Are your clinical trials equipped for a modern world? Prior to 2020, the answer was likely not very much.

Disruptions due to COVID-19 paired with a slew of new guidance from regulatory bodies has catapulted the clinical trial industry into a period of digital transformation.1 More sponsors and CROs are beginning to adopt decentralized solutions and embrace digital workflows, yet informed consent continues to rely heavily on paper-based processes. Lots and lots of paper.

Hybrid clinical trial models aren’t new, but they have grown from a novelty to a necessity over the past decade.1 While the benefits of hybrid trials cannot be overstated, many decision makers still view it as a temporary measure. Others remain weary or unsure of how to take the first steps into hybrid decentralized studies, let alone embrace it on a wide scale.

The nature of managing clinical research has evolved greatly since the initial clinical trial management systems (CTMS) and other early eClinical technologies were introduced. As the traditional trial paradigm has shifted, new technologies have been introduced and existing ones have evolved to keep up with the industry.

There’s no denying that the medical device industry has seen a tidal wave of competition in recent years. Forbes forecasted that this $518 billion industry will be a disruptor in the healthcare technology space through 2023, if not longer.

This webinar session focused on how Medrio’s integrated RTSM solution can be optimized to reduce the noise of complicated clinical trials and leave you with clear, actionable data for better supply management.